Curia Releases 2024 Environmental, Social and Governance (ESG) Report
28 de outubro de 2025
ALBANY, N.Y., Oct. 28, 2025 (GLOBE NEWSWIRE) — Curia Global, Inc. (Curia), a leading contract research, development and manufacturing organization, today announced the release of its third Environmental, Social and Governance (ESG) report. This latest report highlights the companys new C.U.R.I.A. Way valuescuriosity, urgency, respect, integrity and accountabilityand how those values are woven into its mission, purpose and corporate responsibility initiatives.
Key accomplishments from the report include:
In 2024, Curia committed to setting near-and long-term company-wide GHG emission reductions in line with climate science through the Science Based Target Initiative (SBTi) and joined the United Nations Race to Zero campaign, a global coalition of non-state entities working toward halving global emissions by 2030.
Curias French facilities in Bon Encontre and Tonneins achieved ISO 9001, 45001 and 14001 certifications, and its sites in Origgio and Rozzano, Italy, achieved ISO 45001 and 14001 certifications. The companys EHS Management System continues to mirror ISO 14001 and 45001 standards across all sites.
85% of Curias facilities exceeded one year without a recordable injury, with nine sites exceeding more than two years.
Employees voluntarily devoted over 10,000 hours to learning on the companys iLearn platform, powered by Skillsofts Percipio technology, which continues to offer learning resources for exempt-level employees globally.
Curias DE&I Council continues to expand with a focus on providing a forum for discussion and a path for advancement for all employees.
Our latest ESG report reflects our progress as a leader in the industry from reducing our environmental footprint to fostering a culture of safety, integrity and responsibility, said Philip Macnabb, CEO of Curia. As Curia continues to evolve, we know there is still more work to be done. Our ESG initiatives remain deeply intertwined with our approach to scientific innovation and operational excellence as we serve our customers and their patients.
About Curia Curia is a contract research, development and manufacturing organization (CDMO) with over 30 years of experience, an integrated network of 20+ global sites and 3,200 employees, partnering with biopharmaceutical customers to bring life-changing therapies to market. Our offerings in small molecule, generic APIs and biologics span discovery through commercialization, with integrated regulatory, analytical and sterile fill-finish capabilities. Our scientific and process experts, along with our regulatory compliant facilities, provide a best-in-class experience across drug substance and drug product manufacturing. From curiosity to cure, we deliver every step to accelerate your research and improve patients lives. Visit us at curiaglobal.com.
A OESP nao e(sao) responsavel(is) por erros, incorrecoes, atrasos ou quaisquer decisoes tomadas por seus clientes com base nos Conteudos ora disponibilizados, bem como tais Conteudos nao representam a opiniao da OESP e sao de inteira responsabilidade da GlobeNewswire
